Document | Fichier |
---|---|
Fichier pdf chargé le 08/01/2015 à 10:17:12 (version éditeur) | fichier |
Titre | In vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery |
Type de publication | Article de revue |
Auteur | Rivera-Rodriguez, Gustavo R, Lollo, Giovanna , Montier, Tristan, Benoît, Jean-Pierre , Passirani-Malleret, Catherine, Alonso, Maria José, Torres, Dolores |
Editeur | Elsevier |
Type | Article scientifique dans une revue à comité de lecture |
Année | 2013 |
Langue | Anglais |
Date | 2013 Dec 15 |
Numéro | 1 |
Pagination | 83-9 |
Volume | 458 |
Titre de la revue | International Journal of Pharmaceutics |
ISSN | 1873-3476 |
Mots-clés | Animals, Antineoplastic Agents, Asparagine, Cell Line, Tumor, Chemistry, Pharmaceutical, Drug Carriers, Drug Delivery Systems, Glioma, Mice, Nanocapsules, Particle Size, Taxoids, Tissue Distribution |
Résumé en anglais | Here, we report the in vivo proof of-concept of a novel nanocarrier, poly-l-asparagine (PASN) nanocapsules, as an anticancer targeted drug delivery system. The nanocapsules were loaded with the fluorescent marker DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate) and also with the model drug docetaxel to evaluate the biodistribution and efficacy profiles in healthy and glioma-bearing mice, respectively. Regardless of their cargo, the nanocapsules presented a size close to 180 nm, a surface charge around -40 mV and an encapsulation efficiency of 75-90%. The biodistribution study in healthy mice showed that PASN nanocapsules led to a two- and three-fold increment in the mean residence time (MRT) and area under the curve (AUC) values, respectively, compared to those of a non-polymeric nanoemulsion. Finally, the efficacy/toxicity study indicated that the encapsulated drug was as efficacious as the commercial formulation (Taxotere(®)), with the additional advantage of being considerably less toxic. Overall, these results suggest the potential of PASN nanocapsules as drug nanocarriers in anticancer therapy. |
URL de la notice | http://okina.univ-angers.fr/publications/ua6672 |
DOI | 10.1016/j.ijpharm.2013.09.038 |
Lien vers le document | |
Autre titre | Int J Pharm |
Identifiant (ID) PubMed | 24140546 |